Showing results (31-40 of 54) with videos related to
Sort By:
Pageof 6
Biosensors & Bioelectronics|January 1, 1995
Impedance based sensing of the specific binding reaction between Staphylococcus enterotoxin B and its antibody on an ultra-thin platinum filmM S DeSilva, Y Zhang, P J Hesketh, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal studyP J Hesketh, G Rossi, G Rizzi, et al.The Cancer Journal From Scientific American|May 1, 1997
Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasoneP J Hesketh, D R Gandara, A M Hesketh, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 21, 2023
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agentsJørn Herrstedt, L Celio, P J Hesketh, et al.Cancer Investigation|April 9, 2001
Paclitaxel, cisplatin, and concurrent radiation for esophageal cancerH Safran, H Gaissert, P Akerman, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 17, 1998
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trialsJ B Whitmore, M G Kris, P J Hesketh, et al.Seminars in Oncology|August 1, 1992
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placeboD R Gandara, W H Harvey, G G Monaghan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapyR J Gralla, R M Navari, P J Hesketh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Proposal for classifying the acute emetogenicity of cancer chemotherapyP J Hesketh, M G Kris, S M Grunberg, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 2, 2006
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment responseP J Hesketh, S M Grunberg, J Herrstedt, et al.Pageof 6